Sinclair Pharma and Orapharma mutually agree to terminate US distribution agreement for Decapinol

13-Nov-2009 - United Kingdom

Sinclair Pharma plc announced that it has mutually agreed with Orapharma Inc to terminate with immediate effect their distribution agreement for Decapinol mouth rinse, known as Impede, in the US. Decapinol is a product for treating gingivitis and plaque and preventing periodontitis. Orapharma, a Johnson & Johnson subsidiary, held US rights to the niche market of sale and promotion to dental professionals.

The effect of this termination is that Sinclair is immediately free to license and reposition the product for a much larger target market, including the over-the-counter (OTC) market in the US. The agreement with Orapharma effectively meant the product would not reach the OTC market for some years. Sinclair is in discussions about the opportunities and is confident that the long term benefit to shareholders can outweigh any short-term loss of potential milestone income from Orapharma.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances